Efficacy and tolerability of blonanserin versus aripiprazole in Japanese patients with psychotic disorder: a randomized, masked-rater trial

Efficacy and tolerability of blonanserin versus aripiprazole in Japanese patients with psychotic disorder: a randomized, masked-rater trial - A randomized controlled trial of blonanserin versus aripiprazole in psychotic disorder

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011194

Enrollment

100

Registered

2013-07-16

Start date

2013-07-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psychotic disorder

Interventions

Blonanserin Aripiprazole

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Schizophrenia, schizoaffective disorder, schizophreniform disorder based on DSM-4-TR The patients did not take any antisychotics for more than 2 weeks

Exclusion criteria

Exclusion criteria: Patients with coma. Patients take barbiturate, anesthetic, adrenaline, psychostimulant or.and alocohol. Patients with allergies to blonanserin and aripiprazole Patients who are pregnant or may become pregnant Patients with personality disorder or mental retardation. ients with dementina.

Design outcomes

Primary

Measure	Time frame
PANSS	—

Countries

Japan

Contacts

Public ContactTaro Kishi

Fujita Health University School of Medicine Department of Psychiatry

tarok@fujita-hu.ac.jp0562939250

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026